Anlon Healthcare (NSE:AHCL) YoY EBITDA Growth: 149.15% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AHCL Anlon Healthcare Ltd NSE:AHCL
21 GF Score
Price ₹22.90
! 6 Warning Signs
View Full Analysis

What is Anlon Healthcare YoY EBITDA Growth?

Anlon Healthcare NSE:AHCL +4.85% 21 YoY EBITDA Growth is 149.15% as of Jun. 2026. GuruFocus rates NSE:AHCL with a GF Score™ of 21/100. The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Anlon Healthcare's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 149.15%.

Anlon Healthcare's EBITDA per Share for the three months ended in Jun. 2026 was ₹0.29.

Anlon Healthcare YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Anlon Healthcare's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anlon Healthcare YoY EBITDA Growth Chart

Anlon Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
- 115.46 22.79 105.84 67.61

Anlon Healthcare Quarterly Data
Jun24 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial - - - 125.00 149.15
NSE:AHCL
21GF Score
Anlon Healthcare Ltd NSE:AHCL
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anlon Healthcare YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Anlon Healthcare's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(1.004-0.599)/ | 0.599 |
=67.61 %

Anlon Healthcare's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.294-0.118)/ | 0.118 |
=149.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 149.15% mean?
Anlon Healthcare (NSE:AHCL) has a YoY EBITDA Growth of 149.15% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Anlon Healthcare and its competitors.
Is Anlon Healthcare's YoY EBITDA Growth too high?
Anlon Healthcare's current YoY EBITDA Growth is 149.15%. Overall, Anlon Healthcare has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's YoY EBITDA Growth compare to ZTS?
Anlon Healthcare's YoY EBITDA Growth of 149.15% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Anlon Healthcare and its competitors. Anlon Healthcare's current YoY EBITDA Growth is 149.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current YoY EBITDA Growth of 149.15%. The current YoY EBITDA Growth is 149.15%. Anlon Healthcare's overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current YoY EBITDA Growth is 149.15% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anlon Healthcare Business Description

Other Exchanges 544497:India
Address Kalawad Road, 101/102, Silvercoin Complex, Opposite Crystal Mall, Rajkot, GJ, IND, 360 005
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
21GF Score

Get the complete analysis for NSE:AHCL

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹22.90
Price